Воспалительные заболевания органов малого таза: просто о сложном

1. Sweet RL, Gibbs RS. Pelvic inflammatory disease. In: Infectious diseases of female genital tract. Philadelphia: Lippincott Williams & Wilkins, 2009; p. 220–44.
2. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. Morbidity and Mortality Weekly Report 2010; 59 (RR-12): 110.
3. Westrom LV. Sexually transmitted diseases and infertility. Sexually Transmitted Diseases 1994; 21 (Suppl.): 532–7.
4. Westrom LV, Joesoef R, Reynolds G et al. Pelvic inflammatory disease and infertility. A cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sexually Transmitted Diseases 1992; 19: 185–92.
5. Westrom LV, Berger GS. Consequences of pelvic inflammatory disease. Pelvic inflammatory disease. New York: Raven Press, 1992; p. 101–14.
6. Hillis SD, Joesoef R, Marchbanks PA et al. Delayed care of pelvic inflammatory disease is a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168: 1503–9.
7. Ross J, Judlin P, Nilas L. European guideline for the management of pelvic inflammatory disease. Int J STD AIDS 2007; 18: 662–6.
8. Sweet RL. Treatment of acute pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011.
9. Ness RB, Soper DE, Holley RL et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the pelvic inflammatory disease evaluation and clinical health (PEACH) randomized trial. Am J Obstet Gynecol 2002; 186 (5): 929–37.
10. Manhart LE, Critchlow CW, Holmes KK et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis 2003; 187 (4): 650–7.
11. Pépin J, Labbé A.-C., Khonde N et al. Mycoplasma qenitalium: an organism commonly associated with cervicitis among west African sex workers. Sex Transmit Infect 2005; 81 (1): 67–72.
12. Moller BR, Taylor-Robinson D, Furr PM, Freundt EA. Acute upper genital-tract disease in female monkeys provoked experimentally by Mycoplasma genitalium. Br J Experiment Pathology 1985; 66 (4): 417–26.
13. Barzynska A, Funch P, Fedder J et al. Morphology of human Fallopian tubes after infection with Mycoplasma genitalium and Mycoplasma hominis: In vitro organ culture study. Hum Reprod 2007; 22 (4): 968–79.
14. Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. Смоленск: МАКМАХ, 2007.
15. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40 (5): 639–51.
16. Aldridge KE, Ashcraft DS et al. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemotherapy 1997; 41 (3): 709–11.
17. Woodcock JM, Andrews JM, Boswell FJ et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemotherapy 1997; 41: 101–6.
18. Dalhoff A. In vitro activities of quinolones. Expert opinion on investigational drugs 1999; 8 (2); 123–37.
19. Bebear CM, de Barbeyrac B, Pereyre S et al. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14 (8): 801–5.
20. Sullivan JT, Woodruff M, Lettieri J et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemotherapy 1999; 43 (11): 2793–7.
21. Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102 (2): 132–6.
22. Ross JD, Cronje HS, Paszkowski T et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transmitd Infect 2006; 82 (6): 446–51.
23. Heystek M, Ross JD, PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Internat J STD AIDS 2009; 20 (10): 690–5.
24. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG: Int J Obstet Gynaecol 2010; 117 (12): 1475–84.
25. Mu Y, Huang J, Liu R et al. Efficacy and safety profile of moxifloxacin in treatment of urogenital system infections: A meta-analysis of randomized controlled trials. African J Pharmacy Pharmacol 2012; 6 (26): 1910–22.
26. Walker CK, Sweet RL. Management. In: Sweet RL, Wiesenfeld HC editors. Pelvic Inflammatory Disease. London: Taylor & Francis, 2006; p. 141–56.
27. Ross J, McCarthy G. UK National Guideline for the management of Pelvic Inflammatory Disease 2011. British Association for Sexual Health and HIV, 2011. www.bashh.org/documents/3205.

С.В.Сехин 

ГБОУ ВПО Смоленская государственная медицинская академия Минздрава РФ